The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis
Open accessAbstract
BACKGROUND: Advanced systemic mastocytosis comprises rare hematologic neoplasms that are associated with a poor prognosis and lack effective treatment options. The multikinase inhibitor midostaurin inhibits KIT D816V, a primary driver of disease pathogenesis. METHODS: We conducted an open-label study of oral midostaurin at a dose of 100 mg twice daily in 116 patients, of whom 89 with mastocytosis-related organ damage were eligible for inclusion in the primary efficacy population; 16 had aggressive systemic mastocytosis, 57 had systemic mastocytosis with an associated hematologic neoplasm, and 16 had mast-cell leukemia. The primary outcome was the best overall response. RESULTS: The overall response rate was 60% (95% confidence interval [CI], 49 to 70); 45% of the patients had a major response, which was defined as complete resolution of at least one type of mastocytosis-related organ damage. Response rates were similar regardless of the subtype of advanced systemic mastocytosis, KIT mutation status, or exposure to previous therapy. The median best percentage changes in bone marrow mast-cell burden and serum tryptase level were -59% and -58%, respectively. The median overall survival was 28.7 months, and the median progression-free survival was 14.1 months. Among the 16 patients with mast-cell leukemia, the median overall survival was 9.4 months (95% CI, 7.5 to not estimated). Dose reduction owing to toxic effects occurred in 56% of the patients; re-escalation to the starting dose was feasible in 32% of those patients. The most frequent adverse events were low-grade nausea, vomiting, and diarrhea. New or worsening grade 3 or 4 neutropenia, anemia, and thrombocytopenia occurred in 24%, 41%, and 29% of the patients, respectively, mostly in those with preexisting cytopenias. CONCLUSIONS: In this open-label study, midostaurin showed efficacy in patients with advanced systemic mastocytosis, including the highly fatal variant mast-cell leukemia. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT00782067.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Cheson, B. D. (2006) · Blood · doi:10.1182/blood-2005-10-4149 · Cited by 1,580
Portenoy, R. K., Thaler, H. T., Kornblith, A. B., McCarthy Lepore, J., Friedlander-Klar, H., Kiyasu, E., Sobel, K., Coyle, N., Kemeny, N., Norton, L., et al. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90182-1 · Cited by 1,577
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Diagnostic criteria and classification of mastocytosis: a consensus proposal
Valent, P., Horny, H.-P., Escribano, L., Longley, B. J., Li, C. Y., Schwartz, L. B., Marone, G., Nuñez, R., Akin, C., Sotlar, K., et al. (2001) · Leukemia Research · doi:10.1016/s0145-2126(01)00038-8 · Cited by 1,108
Self-citationUser’s manual for the SF-12v2 health survey
Ware, J., Kosinski, M., Bowker, D., Gandek, B., Ware, J. E., & Turner‐Bowker, D. M. (2002) · Cited by 1,085
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750
Self-citationCheson, B. D., Bennett, J. M., Kantarjian, H. M., Pinto, A., Schiffer, C. A., Nimer, S. D., Löwenberg, B., Beran, M., de Witte, T. M., Stone, R. M., et al. (2000) · PubMed · Cited by 666
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Lim, K.-H., Tefferi, A., Lasho, T. L., Finke, C., Patnaik, M., Butterfield, J. H., McClure, R. F., Li, C.-Y., & Pardanani, A. (2009) · Blood · doi:10.1182/blood-2009-02-205237 · Cited by 588
WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
(2007) · CRC Desk Reference for Hematology · doi:10.1201/9781420005127.ax1 · Cited by 497
PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro, D., Ruetz, S., Bodis, S. B., Pruschy, M. N., Csermak, K., Man, A., Campochiaro, P. A., Wood, J. M., O'Reilly, T., & Meyer, T. (2000) · PubMed · Cited by 271
Comprehensive mutational profiling in advanced systemic mastocytosis
Schwaab, J., Schnittger, S., Sotlar, K., Walz, C., Fabarius, A., Pfirrmann, M., Kohlmann, A., Grossmann, V., Meggendorfer, M., Horny, H.-P., et al. (2013) · Blood · doi:10.1182/blood-2013-04-496448 · Cited by 263
Self-citationGrowney, J. D., Clark, J. J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J. D., & Gilliland, D. G. (2005) · Blood · doi:10.1182/blood-2004-12-4617 · Cited by 249
Cladribine therapy for systemic mastocytosis
Kluin-Nelemans, H. C. (2003) · Blood · doi:10.1182/blood-2003-05-1699 · Cited by 248
Self-citationGotlib, J. (2005) · Blood · doi:10.1182/blood-2005-04-1568 · Cited by 243
Self-citationEpidemiology of systemic mastocytosis in Denmark
Cohen, S. S., Skovbo, S., Vestergaard, H., Kristensen, T., Møller, M., Bindslev‐Jensen, C., Fryzek, J. P., & Broesby‐Olsen, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.12916 · Cited by 234
Valent, P. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00168-6 · Cited by 234
Self-citationKristensen, T., Vestergaard, H., & Møller, M. B. (2011) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2010.10.004 · Cited by 208
Lim, K. H., Pardanani, A., Butterfield, J. H., Li, C., & Tefferi, A. (2009) · American Journal of Hematology · doi:10.1002/ajh.21561 · Cited by 194
Hematopoietic Stem-Cell Transplantation for Advanced Systemic Mastocytosis
Ustun, C., Reiter, A., Scott, B. L., Nakamura, R., Damaj, G., Kreil, S., Shanley, R., Hogan, W. J., Perales, M.-A., Shore, T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2018 · Cited by 190
Self-citationGeorgin-Lavialle, S., Lhermitte, L., Dubreuil, P., Chandesris, M.-O., Hermine, O., & Damaj, G. (2013) · Blood · doi:10.1182/blood-2012-07-442400 · Cited by 178
Self-citationSotlar, K., Colak, S., Bache, A., Berezowska, S., Krokowski, M., Bültmann, B., Valent, P., & Horny, H. (2010) · The Journal of Pathology · doi:10.1002/path.2677 · Cited by 165
Self-citationTreatment of Systemic Mast-Cell Disease with Cladribine
Tefferi, A., Li, C.-Y., Butterfield, J. H., & Hoagland, H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101253440415 · Cited by 162
Jawhar, M., Schwaab, J., Schnittger, S., Sotlar, K., Horny, H. ‐., Metzgeroth, G., Müller, N., Schneider, S. O., Naumann, N., Walz, C., et al. (2015) · Leukemia · doi:10.1038/leu.2015.4 · Cited by 156
Self-citationLong-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis
Barète, S., Lortholary, O., Damaj, G. L., Hirsch, I., Chandesris, M., Elie, C., Hamidou, M. A., Durieu, I., Suárez, F., Grosbois, B., et al. (2015) · Blood · doi:10.1182/blood-2014-12-614743 · Cited by 151
Self-citationGotlib, J. R., Pardanani, A. D., Akin, C., Reiter, A., George, T. I., Hermine, O., Kluin‐Nelemans, H. C., Hartmann, K., Sperr, W. R., Brockow, K., et al. (2013) · Blood · doi:10.1182/blood-2012-09-458521 · Cited by 145
Self-citationHauswirth, A. W., Simonitsch‐Klupp, I., Uffmann, M., Koller, E., Sperr, W. R., Lechner, K., & Valent, P. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00259-5 · Cited by 142
Self-citationKrauth, M. T., Mirkina, I. I., Herrmann, H., Baumgärtner, C., Kneidinger, M., & Valent, P. (2009) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2009.03353.x · Cited by 90
Self-citationSystemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management
Pardanani, A. D. (2015) · American Journal of Hematology · doi:10.1002/ajh.23931 · Cited by 89
Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine
Pardanani, A. D., Hoffbrand, A. V., Butterfield, J. H., & Tefferi, A. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00185-1 · Cited by 87
lnterferon-α in combination with corticosteroids improves systemic mast cell disease
Delaporte, E., Pierard, E., Wolthers, B. G., Desreumaux, P., Janin, A., Cortot, A., Piette, F., & Bergoend, H. (1995) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb08689.x · Cited by 57
Gotlib, J. R., DeAngelo, D. J., George, T. I., Corless, C. L., Linder, A., Langford, C., Dutreix, C., Gross, S. H., Nikolova, Z. G., & Graubert, T. A. (2010) · Blood · doi:10.1182/blood.v116.21.316.316 · Cited by 51
Self-citationNew Insights into the Pathogenesis, Diagnosis, and Management of Mastocytosis
Fuller, S. J. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.08.008 · Cited by 28
c-kit Mutational Analysis in Paraffin Material
Sotlar, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-357-2_4 · Cited by 10
Self-citation
Cited by
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts
Valent, P., Akin, C., & Metcalfe, D. D. (2017) · Blood · doi:10.1182/blood-2016-09-731893 · Cited by 592
Self-citationAnaphylaxis: A 2023 practice parameter update
Golden, D. B. K., Wang, J., Waserman, S., Akin, C., Campbell, R. L., Ellis, A. K., Greenhawt, M., Lang, D. M., Ledford, D. K., Lieberman, J., et al. (2024) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2023.09.015 · Cited by 347
Self-citationUpdated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Valent, P., Akin, C., Hartmann, K., Alvarez-Twose, I., Brockow, K., Hermine, O., Niedoszytko, M., Schwaab, J., Lyons, J. J., Carter, M. C., et al. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000646 · Cited by 317
Self-citationMidostaurin approved for FLT3-mutated AML
Levis, M. (2017) · Blood · doi:10.1182/blood-2017-05-782292 · Cited by 291
Metadata
- Authors
- Gotlib, J., Kluin-Nelemans, H. C., George, T. I., Akin, C., Sotlar, K., Hermine, O., Awan, F. T., Hexner, E., Mauro, M. J., Sternberg, D. W., Villeneuve, M., Huntsman Labed, A., Stanek, E. J., Hartmann, K., Horny, H.-P., Valent, P., & Reiter, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-30
- Volume
- 374
- Issue
- 26
- Pages
- 2530-2541
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2472403803
- Cited by
- 488
- References
- 37
- FWCI
- 29.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.